265 related articles for article (PubMed ID: 30676731)
1. Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth.
Lang J; Zhao X; Wang X; Zhao Y; Li Y; Zhao R; Cheng K; Li Y; Han X; Zheng X; Qin H; Geranpayehvaghei M; Shi J; Anderson GJ; Hao J; Ren H; Nie G
ACS Nano; 2019 Feb; 13(2):2176-2189. PubMed ID: 30676731
[TBL] [Abstract][Full Text] [Related]
2. Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine.
Komoto K; Nomoto T; El Muttaqien S; Takemoto H; Matsui M; Miura Y; Nishiyama N
Cancer Sci; 2021 Jan; 112(1):410-421. PubMed ID: 32770631
[TBL] [Abstract][Full Text] [Related]
3. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.
Ford SJ; Obeidy P; Lovejoy DB; Bedford M; Nichols L; Chadwick C; Tucker O; Lui GY; Kalinowski DS; Jansson PJ; Iqbal TH; Alderson D; Richardson DR; Tselepis C
Br J Pharmacol; 2013 Mar; 168(6):1316-28. PubMed ID: 23126308
[TBL] [Abstract][Full Text] [Related]
4. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
Darnell G; Richardson DR
Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
[TBL] [Abstract][Full Text] [Related]
5. Deferoxamine-mediated up-regulation of HIF-1α prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-treated mice.
Guo C; Hao LJ; Yang ZH; Chai R; Zhang S; Gu Y; Gao HL; Zhong ML; Wang T; Li JY; Wang ZY
Exp Neurol; 2016 Jun; 280():13-23. PubMed ID: 26996132
[TBL] [Abstract][Full Text] [Related]
6. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
Richardson D; Ponka P; Baker E
Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
[TBL] [Abstract][Full Text] [Related]
7. The iron chelator desferrioxamine synergizes with chemotherapy for cancer treatment.
Wang L; Li X; Mu Y; Lu C; Tang S; Lu K; Qiu X; Wei A; Cheng Y; Wei W
J Trace Elem Med Biol; 2019 Dec; 56():131-138. PubMed ID: 31466045
[TBL] [Abstract][Full Text] [Related]
8. Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo.
Wang Y; Liu Z; Lin TM; Chanana S; Xiong MP
Int J Pharm; 2018 Mar; 538(1-2):79-86. PubMed ID: 29341909
[TBL] [Abstract][Full Text] [Related]
9. Local delivery of iron chelators reduces in vivo remodeling of a calcium phosphate bone graft substitute.
Drager J; Sheikh Z; Zhang YL; Harvey EJ; Barralet JE
Acta Biomater; 2016 Sep; 42():411-419. PubMed ID: 27449336
[TBL] [Abstract][Full Text] [Related]
10. The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity.
Umemura M; Kim JH; Aoyama H; Hoshino Y; Fukumura H; Nakakaji R; Sato I; Ohtake M; Akimoto T; Narikawa M; Tanaka R; Fujita T; Yokoyama U; Taguri M; Okumura S; Sato M; Eguchi H; Ishikawa Y
J Pharmacol Sci; 2017 Aug; 134(4):203-210. PubMed ID: 28779994
[TBL] [Abstract][Full Text] [Related]
11. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
Porter JB; Rafique R; Srichairatanakool S; Davis BA; Shah FT; Hair T; Evans P
Ann N Y Acad Sci; 2005; 1054():155-68. PubMed ID: 16339661
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.
Zhao X; Li F; Li Y; Wang H; Ren H; Chen J; Nie G; Hao J
Biomaterials; 2015 Apr; 46():13-25. PubMed ID: 25678112
[TBL] [Abstract][Full Text] [Related]
13. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts.
Selig RA; White L; Gramacho C; Sterling-Levis K; Fraser IW; Naidoo D
Cancer Res; 1998 Feb; 58(3):473-8. PubMed ID: 9458092
[TBL] [Abstract][Full Text] [Related]
14. The novel hypoxic cytotoxin, TX-2098 has antitumor effect in pancreatic cancer; possible mechanism through inhibiting VEGF and hypoxia inducible factor-1α targeted gene expression.
Miyake K; Nishioka M; Imura S; Batmunkh E; Uto Y; Nagasawa H; Hori H; Shimada M
Exp Cell Res; 2012 Aug; 318(13):1554-63. PubMed ID: 22472348
[TBL] [Abstract][Full Text] [Related]
15. Deferoxamine-induced increase in the intracellular iron levels in highly aggressive breast cancer cells leads to increased cell migration by enhancing TNF-α-dependent NF-κB signaling and TGF-β signaling.
Liu P; He K; Song H; Ma Z; Yin W; Xu LX
J Inorg Biochem; 2016 Jul; 160():40-8. PubMed ID: 27138103
[TBL] [Abstract][Full Text] [Related]
16. Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells.
Elstner A; Holtkamp N; von Deimling A
Clin Exp Metastasis; 2007; 24(1):57-66. PubMed ID: 17357815
[TBL] [Abstract][Full Text] [Related]
17. Objectives and mechanism of iron chelation therapy.
Hershko C; Link G; Konijn AM; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
[TBL] [Abstract][Full Text] [Related]
18. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
Devanur LD; Evans RW; Evans PJ; Hider RC
Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory Activity of Iron Chelators ATA and DFO on MCF-7 Breast Cancer Cells and Phosphatases PTP1B and SHP2.
Kuban-Jankowska A; Sahu KK; Gorska-Ponikowska M; Tuszynski JA; Wozniak M
Anticancer Res; 2017 Sep; 37(9):4799-4806. PubMed ID: 28870898
[TBL] [Abstract][Full Text] [Related]
20. Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.
Farr AC; Xiong MP
Mol Pharm; 2021 Feb; 18(2):593-609. PubMed ID: 32926630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
